Breast Cancer

Top Story

FDA grants accelerated approval to Keytruda for solid tumors with specific biomarker

May 23, 2017

The FDA today granted accelerated approval to pembrolizumab for adults and children with unresectable or metastatic, microsatellite instability–high or mismatch repair–deficient solid tumors.

This indication for pembrolizumab (Keytruda, Merck) — the FDA’s first tissue/site-agnostic approval — includes patients with solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options, as well as patients with colorectal cancer that has progressed following treatment with fluoropyrimidine, oxaliplatin and irinotecan.

One alcoholic drink per day increases breast cancer risk

May 23, 2017
Women who consume one alcoholic drink per day are at elevated risk for breast cancer, according to a report from the World Cancer Research Fund and American Institute…
In the Journals Plus

Younger age linked to poorer survival from second cancers

May 22, 2017
Younger age at the time of a second primary malignant neoplasm diagnosis appeared linked to worse survival outcomes among cancer survivors, according to a retrospective…

Conquer Cancer Foundation of ASCO to present awards

May 21, 2017
The Conquer Cancer Foundation of ASCO announced the recipients of its Special Merit Awards. Conquer Cancer Foundation Merit Awards support oncology trainees who are…
CME

Hot Topics in Metastatic Breast Cancer Management: Clinical Advances with CDK4/6 Inhibitors

This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.

While the mortality rates for advanced or metastatic breast cancer (MBC) have steadily decreased, in part due to…
More »
Video
Meeting News Coverage

VIDEO: Mouthwash reduces everolimus-related stomatitis in women with breast cancer

January 10, 2017
More »
Featured
ASCO Annual Meeting

ASCO Annual Meeting

FDA News

FDA grants accelerated approval to Keytruda for solid tumors with specific biomarker

May 23, 2017
The FDA today granted accelerated approval to pembrolizumab for adults and children with unresectable or metastatic, microsatellite…

One alcoholic drink per day increases breast cancer risk

May 23, 2017
Women who consume one alcoholic drink per day are at elevated risk for breast cancer, according to a report from the World Cancer Research Fund and…

In the Journals Plus

Younger age linked to poorer survival from second cancers

May 22, 2017
Younger age at the time of a second primary malignant neoplasm diagnosis appeared linked to worse survival outcomes among cancer survivors, according…

Conquer Cancer Foundation of ASCO to present awards

May 21, 2017
The Conquer Cancer Foundation of ASCO announced the recipients of its Special Merit Awards. Conquer Cancer Foundation Merit Awards support oncology…

In the Journals Plus

Rare cancers represent 20% of US cancer diagnoses

May 19, 2017
Rare malignancies accounted for about one in five cancer diagnoses in the United States from 2009 to 2013, according to an American Cancer Society…

Study explores disproportionately higher mortality among black cancer survivors

May 19, 2017
Researchers from Barbara Ann Karmanos Cancer Institute and Wayne State University School of Medicine received a 5-year, $9 million grant from NCI to…

Meeting NewsPerspective

Affordable Care Act increases screening, early diagnosis of certain cancers

May 17, 2017
An uptake in cancer screening after implementation of the Affordable Care Act in 2014 has shifted the diagnosis of breast, lung and colorectal…

In the Journals Plus

Axillary surgery may be avoidable for some women with breast cancer

May 16, 2017
Patients with triple-negative or HER-2–positive breast cancer who achieved a complete response after neoadjuvant chemotherapy appeared unlikely…

FDA News

FDA grants breakthrough therapy designation to entrectinib for NTRK fusion–positive solid tumors

May 15, 2017
The FDA granted breakthrough therapy designation to entrectinib for the treatment of NTRK fusion–positive locally advanced or metastatic solid…

In the Journals Plus

Novel antibody-drug conjugate shows promise for advanced triple-negative breast cancer

May 15, 2017
Sacituzumab govitecan — a novel antibody-drug conjugate — produced durable responses and appeared well-tolerated among pretreated

More Headlines »
Advertisement
Advertisement